These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24853277)

  • 1. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
    Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
    Dickinson M; Cherif H; Fenaux P; Mittelman M; Verma A; Portella MSO; Burgess P; Ramos PM; Choi J; Platzbecker U;
    Blood; 2018 Dec; 132(25):2629-2638. PubMed ID: 30305280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    Chawla SP; Staddon A; Hendifar A; Messam CA; Patwardhan R; Kamel YM
    BMC Cancer; 2013 Mar; 13():121. PubMed ID: 23497336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
    Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
    Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
    Duong VH; Al Ali N; Zhang L; Padron E; Sallman D; Lancet JE; List AF; Komrokji RS
    Leuk Lymphoma; 2020 Aug; 61(8):1901-1907. PubMed ID: 32306798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
    Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
    Sternberg A; Boucher R; Coulthard HC; Raghavan M; Culligan D; Jackson A; Cargo C; Dennis M; Metzner M; O'Sullivan J; Moore R; Bowen D; Vyas P
    Br J Haematol; 2022 Oct; 199(2):222-229. PubMed ID: 35918828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
    Katsutani S; Tomiyama Y; Kimura A; Miyakawa Y; Okamoto S; Okoshi Y; Ninomiya H; Kosugi H; Ishii K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    Int J Hematol; 2013 Sep; 98(3):323-30. PubMed ID: 23896965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
    Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
    Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.